bendazac has been researched along with Cataract in 9 studies
bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.
Cataract: Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bendazac is a non-steroidal anti-inflammatory drug able to delay the cataractogenic process." | 5.29 | Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent. ( Capezzone De Joannon, A; Cavallo, G; Cazzolla, N; Guglielmotti, A; Marchetti, M; Pinza, M; Soldo, L, 1995) |
| " The final conclusion of our study is that bendazac at a dosage ten-fold lower than that used in the clinics is anticataract drug when orally administered to "BLOA test selected" patients, at least for short term treatment of young, otherwise healthy humans with cortical cataract." | 5.27 | Bendazac and benzydamine for treatment of cataract: individualized therapy by the "BLOA test". ( Buongiovanni, C; Iuliano, G; Marino, E; Mortow, P; Paolercio, F; Testa, M; Trapanese, A, 1986) |
| "This NSAID is used in Spain for the treatment of cataracts, from a total of 112 patients observing such therapy." | 1.29 | [Bendazac hepatotoxicity: analysis of 16 cases]. ( del Portillo Rubí, A; Prada Mínguez, A; Prieto de Paula, JM; Rodríguez Rodríguez, E; Sanz de la Fuente, H; Villamandos Nicás, V, 1995) |
| "Bendazac is a non-steroidal anti-inflammatory drug able to delay the cataractogenic process." | 1.29 | Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent. ( Capezzone De Joannon, A; Cavallo, G; Cazzolla, N; Guglielmotti, A; Marchetti, M; Pinza, M; Soldo, L, 1995) |
| " The final conclusion of our study is that bendazac at a dosage ten-fold lower than that used in the clinics is anticataract drug when orally administered to "BLOA test selected" patients, at least for short term treatment of young, otherwise healthy humans with cortical cataract." | 1.27 | Bendazac and benzydamine for treatment of cataract: individualized therapy by the "BLOA test". ( Buongiovanni, C; Iuliano, G; Marino, E; Mortow, P; Paolercio, F; Testa, M; Trapanese, A, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, H | 1 |
| Gou, S | 1 |
| Shen, J | 1 |
| Zhu, Y | 1 |
| Zhang, Y | 1 |
| Chen, X | 1 |
| Testa, M | 2 |
| Iuliano, G | 2 |
| Silvestrini, B | 1 |
| Prieto de Paula, JM | 1 |
| Rodríguez Rodríguez, E | 1 |
| Villamandos Nicás, V | 1 |
| Sanz de la Fuente, H | 1 |
| Prada Mínguez, A | 1 |
| del Portillo Rubí, A | 1 |
| Guglielmotti, A | 1 |
| Capezzone De Joannon, A | 1 |
| Cazzolla, N | 1 |
| Marchetti, M | 1 |
| Soldo, L | 1 |
| Cavallo, G | 1 |
| Pinza, M | 1 |
| Crabbe, MJ | 1 |
| Hoe, ST | 1 |
| Woollard, AC | 1 |
| Wolff, SP | 1 |
| Bascal, ZA | 1 |
| Ballesteros, JA | 1 |
| Badosa, AM | 1 |
| Usandizaga, I | 1 |
| Amengual, M | 1 |
| Lewis, BS | 1 |
| Harding, JJ | 1 |
| Marino, E | 1 |
| Buongiovanni, C | 1 |
| Paolercio, F | 1 |
| Trapanese, A | 1 |
| Mortow, P | 1 |
1 trial available for bendazac and Cataract
| Article | Year |
|---|---|
Pilot study of bendazac for treatment of cataract.
Topics: Aged; Cataract; Clinical Trials as Topic; Female; Humans; Indazoles; Male; Middle Aged; Pilot Projec | 1982 |
8 other studies available for bendazac and Cataract
| Article | Year |
|---|---|
Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cataract; Indazoles; Lens, Crystalli | 2010 |
[Bendazac hepatotoxicity: analysis of 16 cases].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cataract; Chemical an | 1995 |
Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catalase; Cataract; Female; Flow Cytometry; Free R | 1995 |
Aldehyde dehydrogenase, aldose reductase, and free radical scavengers in cataract.
Topics: Adult; Aged; Aldehyde Dehydrogenase; Aldehyde Reductase; Anti-Inflammatory Agents, Non-Steroidal; Ca | 1991 |
Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract.
Topics: Acetaminophen; Ampyrone; Antioxidants; Aspirin; Biphenyl Compounds; Cataract; Chelating Agents; Eryt | 1990 |
Hepatotoxicity due to bindazac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cataract; Chemical and Drug Induced Liver Injury; Fem | 1987 |
The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis.
Topics: Animals; Cataract; Cattle; Crystallins; Galactose; Glucosephosphates; Glycosylation; In Vitro Techni | 1988 |
Bendazac and benzydamine for treatment of cataract: individualized therapy by the "BLOA test".
Topics: Adult; Age Factors; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzydamine; Cataract; C | 1986 |